ThyGeNEXT
Commercial- Indications
- Thyroid cancer
Company intelligence / Profile preview
Interpace Diagnostics has commercialized several molecular diagnostic tests for oncology indications. Its flagship products are used for the risk stratification of indeterminate thyroid nodules using next-generation sequencing and microRNA profiling. PancraGEN for pancreatic cysts will be discontinued in February 2025 due to reimbursement changes but was previously a key product[6]. BarreGEN remains under clinical evaluation.
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Interpace Diagnostics.